# Nuvation Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuvation-bio

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.nuvationbio.com/
- Total disclosed funding: $275M
- Latest round: Series A (Oct 28, 2019)
- Investors on record: 12

## About

Nuvation Bio, Inc., based in the US, focuses on developing and commercializing innovative oncology medicines, with a commitment to addressing difficult-to-treat cancers through targeted therapies.Nuvation Bio, Inc. specializes in oncology medicine development. Founded in 2018 in New York, US, the firm has completed 2 transactions to date. The latest funding round was a Series A, where they raised USD 275.00 mn led by Omega Funds, with participation from investors including Aisling Capital and Fidelity Investments. The total amount raised by the company now stands at USD 275.00 mn, with the most recent deal occurring on March 3, 2025. David Hung serves as the CEO and has a notable background in the biotech industry.Nuvation Bio, Inc. develops and commercializes innovative oncology medicines, specifically targeting difficult-to-treat cancers. Their flagship product, Taletrectinib (IBTROZI™), has received FDA approval for advanced ROS1+ non-small cell lung cancers. The company is committed to enhancing patient outcomes by addressing drug resistance and the shortcomings of existing therapies. Their pipeline includes various novel therapeutic candidates aimed at critical pathways in cancer growth, catering to a global client base of healthcare providers and oncology specialists, particularly in North America and Europe.Nuvation Bio's revenue is primarily generated through the commercialization of its FDA-approved therapies, particularly Taletrectinib (IBTROZI™). The company's sales transactions occur directly with hospitals and clinics treating cancer patients, involving direct sales and strategic partnerships to ensure the accessibility of their treatments in the oncology market.Nuvation Bio, Inc. plans to utilize the recent USD 250.00 mn venture debt funding raised in March 2025 from Sagard to fully support the U.S. commercial launch of Taletrectinib and to advance its clinical-stage pipeline. The company is targeting expansion into new geographical markets to enhance patient access to its therapies, with specific plans for launching in additional regions by 2025.

## Funding rounds

- Series A, Oct 28, 2019, $275M — Baupost Group, Aisling Capital, Altitude Life Science Ventures, SG Growth Capital, Fidelity Investments, Omega Funds, Redmile Group, Pavilion Capital, EcoR1 Capital, Perceptive Advisors, Boxer Capital, Surveyor Capital

## Investors

- Baupost Group — Series A
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series A
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series A
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series A
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A
- Pavilion Capital — Series A
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series A
- Surveyor Capital — Series A